Recently, researchers from the University of Pennsylvania School of Medicine have discovered a new class of drugs that are effective in treating the most common acute myeloid lymphoma (AML). Mutations in the TLF3 gene are thought to be markers of AML recurrence and death in patients. In the first clinical trial, the researchers used gilteritinib (a class of FLT3 inhibitors) in patients with AML. The results show that the drug is highly tolerant and can perform quite well. The results were published in the journal Lancet Oncology.
FLT3 is one of the most common genetic mutations in AML patients, and mutations in FLT3 are present in 30% of lymphocytes in patients. Clinically, these mutations are accompanied by recurrence of AML and eventual death. In order to avoid the recurrence of tumors, oncologists have used stronger chemotherapy and bone marrow transplantation for AML patients, but these methods do not provide absolute protection. The FLT3 gene is normally expressed in normal bone marrow cells, regulating the normal growth of blood cells. Mutations in FLT3 result in loss of control of lymphocyte growth.
In this clinical trial, Perl et al. examined the therapeutic effect of gilteritinib (ASP2215) in patients with recurrent AML (and no longer responsive to chemotherapy). Of the 252 patients enrolled in the study, 76% had mutations in FLT3. Of these patient populations, 67 in China gave 120 mg of drug stimulation and 100 gave 200 mg of drug stimulation. The results showed that gilteritinib at a dose of 80 mg or more was effective in inhibiting the mutation and activity of FLT3, and this dose range was able to significantly extend the life of the patient. Overall, 49% of patients with FLT3 mutations had a positive response, while only 12% of patients who did not carry the mutation responded to the drug.
In lymphoma cells, further mutations in the FLT3 gene (D835) cause resistance to FLT3 inhibitors, but Gilteritinib exhibits resistance to D835 mutations in a laboratory setting. In clinical trials, Gilteritinib also embodies A considerable therapeutic effect has been produced. In addition, the drug also showed good tolerance.
Currently, researchers hope to compare the efficacy of Gilteritinib with conventional chemotherapy for patients with resistant FLT3 mutant lymphoma, and relevant clinical trials are underway.
Shanghai Chuangsai Technology has excellent performance, interleukin cytokines, fetal bovine serum, electrophoresis equipment scientific instruments, raw material drug standards, chemical reagents, cell culture consumables, Shanghai Chuangsai, mass products special promotions, welcome to inquire!
Sun Lounger,Sun Chair,Garden Sun Loungers,Sun Lounger Chair
Foshan Shunde Zhili Furniture Company , https://www.zhilioutdoor.com